Bristol-Myers Squibb

Insmed appoints Hayden, Jr. as executive chairman

Thursday, May 17, 2012 10:45 AM

Insmed, a Monmouth Junction, N.J.-based biopharmaceutical company focused on inhalants, has appointed Donald J. Hayden, Jr. as executive chairman of the company's board of directors.

More... »

BMS and Tsinghua University form strategic partnership

Wednesday, May 16, 2012 09:57 AM

Bristol-Myers Squibb and Tsinghua University of Beijing have entered into a multi-year strategic partnership.

More... »

Recipients of 2012 SAFE-Biopharma Digi Award named

Monday, April 30, 2012 04:52 PM

Recipients have been selected for the 2012 SAFE-BioPharma Digi Award, recognizing innovative uses of the global SAFE-BioPharma digital identity and digital signature standard and the institutions and individuals contributing to broader understanding of its benefits. Recipients included: Astellas, Bristol-Myers Squibb and representatives of two U.S. government entities.

More... »

Burrill wraps up life sciences industry for Q1 2012

Wednesday, April 4, 2012 03:00 PM

Burrill & Company, a diversified global financial services firm focused on the life sciences industry, has identified more than $2.6 billion in expected funding through nine translational research and early-stage initiatives announced since the end of February.

More... »

BMS and Duke form strategic relationship

Wednesday, February 29, 2012 02:31 PM

Bristol-Myers Squibb (BMS) and Duke Translational Medicine Institute (DTMI) have formed a strategic relationship to broaden interactions between the two organizations.

More... »

Patheon promotes Mancuso

Tuesday, January 31, 2012 08:30 AM

Patheon, a global provider of drug development and manufacturing services, has promoted Antonella Mancuso to president, global commercial operations and chief manufacturing officer, responsible for Patheon's global commercial  manufacturing operations. Mancuso will assume responsibility for all of Patheon's commercial operating units in North America and Europe. 

More... »

Hep C suppressed by combination of oral drugs

Friday, January 20, 2012 03:10 PM

A new combination of investigational drugs successfully suppressed hepatitis C genotype I infection in a high percent of patients who had not responded to previous treatment in a study led by a University of Michigan hepatologist.

More... »

Bristol-Myers Squibb to acquire Inhibitex

Monday, January 9, 2012 03:59 PM

Bristol-Myers Squibb has agreed to acquire Inhibitex, a biopharmaceutical company, for $26 per share, or approximately $2.5 billion, in cash.

More... »

Bristol-Myers Squibb, Simcere partner to develop cardiovascular compound

Wednesday, December 14, 2011 04:35 PM

Bristol-Myers Squibb and Simcere Pharmaceutical Group have expanded the strategic partnership formed last year to include a second collaboration in a different therapeutic area. The companies agreed to co-develop BMS-795311, Bristol-Myers Squibb's preclinical small molecule inhibitor of the Cholesteryl Ester Transfer Protein (CETP).  Inhibiting CETP could potentially raise HDL levels and help prevent cardiovascular disease.

More... »

Bristol Myers enters clinical collaboration with Tibotec

Friday, December 2, 2011 11:35 AM

Bristol-Myers Squibb has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals, one of the Janssen Pharmaceutical companies, to evaluate the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb’s investigational NS5A replication complex inhibitor, in combination with Tibotec Pharmaceuticals' investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV).

More... »